Anna-Eliane Hopf1, Christian Andresen1, Sebastian Kötter1, Małgorzata Isić1, Kamila Ulrich2, Senem Sahin1, Sabine Bongardt1, Wilhelm Röll3, Felicitas Drove4, Nina Scheerer4, Leni Vandekerckhove5, Gilles W De Keulenaer5, Nazha Hamdani2, Wolfgang A Linke6, Martina Krüger7. 1. From the Medical Faculty, Department of Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany (A.-E.H., C.A., S.K., M.I., S.S., S.B., M.K.). 2. Department of Systems Physiology, Ruhr-University Bochum, Germany (K.U., N.H.). 3. Department of Cardiovascular Surgery, University Clinic Bonn, Germany (W.R.). 4. Bayer AG, Drug Discovery, Pharmaceuticals, Wuppertal, Germany (F.D., N.S.). 5. Department of Pharmaceutical Sciences, Laboratory of Physiopharmacology, Campus Drie Eiken, University of Antwerp, Belgium (L.V., G.W.D.). 6. Institute of Physiology II, University of Munster, Germany (W.A.L.). 7. From the Medical Faculty, Department of Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany (A.-E.H., C.A., S.K., M.I., S.S., S.B., M.K.) martina.krueger@uni-duesseldorf.de.
Abstract
RATIONALE: Increased titin-dependent cardiomyocyte tension is a hallmark of heart failure with preserved ejection fraction associated with type-2 diabetes mellitus. However, the insulin-related signaling pathways that modify titin-based cardiomyocyte tension, thereby contributing to modulation of diastolic function, are largely unknown. OBJECTIVE: We aimed to determine how impaired insulin signaling affects titin expression and phosphorylation and thus increases passive cardiomyocyte tension, and whether metformin or neuregulin-1 (NRG-1) can correct disturbed titin modifications and increased titin-based stiffness. METHODS AND RESULTS: We used cardiac biopsies from human diabetic (n=23) and nondiabetic patients (n=19), cultured rat cardiomyocytes, left ventricular tissue from apolipoprotein E-deficient mice with streptozotocin-induced diabetes mellitus (n=12-22), and ZSF1 (obese diabetic Zucker fatty/spontaneously hypertensive heart failure F1 hybrid) rats (n=5-6) and analyzed insulin-dependent signaling pathways that modulate titin phosphorylation. Titin-based passive tension was measured using permeabilized cardiomyocytes. In human diabetic hearts, we detected titin hypophosphorylation at S4099 and hyperphosphorylation at S11878, suggesting altered activity of protein kinases; cardiomyocyte passive tension was significantly increased. When applied to cultured cardiomyocytes, insulin and metformin increased titin phosphorylation at S4010, S4099, and S11878 via enhanced ERK1/2 (extracellular signal regulated kinase 1/2) and PKCα (protein kinase Cα) activity; NRG-1 application enhanced ERK1/2 activity but reduced PKCα activity. In apolipoprotein E-deficient mice, chronic treatment of streptozotocin-induced diabetes mellitus with NRG-1 corrected titin phosphorylation via increased PKG (protein kinase G) and ERK1/2 activity and reduced PKCα activity, which reversed the diabetes mellitus-associated changes in titin-based passive tension. Acute application of NRG-1 to obese ZSF1 rats with type-2 diabetes mellitus reduced end-diastolic pressure. CONCLUSIONS: Mechanistically, we found that impaired cGMP-PKG signaling and elevated PKCα activity are key modulators of titin-based cardiomyocyte stiffening in diabetic hearts. We conclude that by restoring normal kinase activities of PKG, ERK1/2, and PKCα, and by reducing cardiomyocyte passive tension, chronic NRG-1 application is a promising approach to modulate titin properties in heart failure with preserved ejection fraction associated with type-2 diabetes mellitus.
RATIONALE: Increased titin-dependent cardiomyocyte tension is a hallmark of heart failure with preserved ejection fraction associated with type-2 diabetes mellitus. However, the insulin-related signaling pathways that modify titin-based cardiomyocyte tension, thereby contributing to modulation of diastolic function, are largely unknown. OBJECTIVE: We aimed to determine how impaired insulin signaling affects titin expression and phosphorylation and thus increases passive cardiomyocyte tension, and whether metformin or neuregulin-1 (NRG-1) can correct disturbed titin modifications and increased titin-based stiffness. METHODS AND RESULTS: We used cardiac biopsies from humandiabetic (n=23) and nondiabeticpatients (n=19), cultured rat cardiomyocytes, left ventricular tissue from apolipoprotein E-deficientmice with streptozotocin-induced diabetes mellitus (n=12-22), and ZSF1 (obese diabetic Zucker fatty/spontaneously hypertensive heart failure F1 hybrid) rats (n=5-6) and analyzed insulin-dependent signaling pathways that modulate titin phosphorylation. Titin-based passive tension was measured using permeabilized cardiomyocytes. In humandiabetic hearts, we detected titin hypophosphorylation at S4099 and hyperphosphorylation at S11878, suggesting altered activity of protein kinases; cardiomyocyte passive tension was significantly increased. When applied to cultured cardiomyocytes, insulin and metformin increased titin phosphorylation at S4010, S4099, and S11878 via enhanced ERK1/2 (extracellular signal regulated kinase 1/2) and PKCα (protein kinase Cα) activity; NRG-1 application enhanced ERK1/2 activity but reduced PKCα activity. In apolipoprotein E-deficientmice, chronic treatment of streptozotocin-induced diabetes mellitus with NRG-1 corrected titin phosphorylation via increased PKG (protein kinase G) and ERK1/2 activity and reduced PKCα activity, which reversed the diabetes mellitus-associated changes in titin-based passive tension. Acute application of NRG-1 to obese ZSF1 rats with type-2 diabetes mellitus reduced end-diastolic pressure. CONCLUSIONS: Mechanistically, we found that impaired cGMP-PKG signaling and elevated PKCα activity are key modulators of titin-based cardiomyocyte stiffening in diabetic hearts. We conclude that by restoring normal kinase activities of PKG, ERK1/2, and PKCα, and by reducing cardiomyocyte passive tension, chronic NRG-1 application is a promising approach to modulate titin properties in heart failure with preserved ejection fraction associated with type-2 diabetes mellitus.
Authors: Maria Papadaki; Ronald J Holewinski; Samantha Beck Previs; Thomas G Martin; Marisa J Stachowski; Amy Li; Cheavar A Blair; Christine S Moravec; Jennifer E Van Eyk; Kenneth S Campbell; David M Warshaw; Jonathan A Kirk Journal: JCI Insight Date: 2018-10-18
Authors: Yi Tan; Zhiguo Zhang; Chao Zheng; Kupper A Wintergerst; Bradley B Keller; Lu Cai Journal: Nat Rev Cardiol Date: 2020-02-20 Impact factor: 32.419
Authors: Zhao Li; Vineet Agrawal; Mohun Ramratnam; Ravi K Sharma; Stephen D'Auria; Abigail Sincoular; Margurite Jakubiak; Meredith L Music; William J Kutschke; Xueyin N Huang; Lindsey Gifford; Ferhaan Ahmad Journal: Cardiovasc Res Date: 2019-09-01 Impact factor: 10.787
Authors: Ramone Eldemire; Charles A Tharp; Matthew R G Taylor; Orfeo Sbaizero; Luisa Mestroni Journal: Curr Cardiol Rep Date: 2021-07-16 Impact factor: 3.955